Neurodevelopmental Theories of Adolescent Mental Health: The Cases of Puberty and Early Adversity

Jennifer H. Pfeifer, Ph.D. Department of Psychology



I. Puberty




Why study puberty?


- ABCD workshop
- Common definition of adolescence: Adolescence has a biological beginning in puberty – and a social ending with the assumption of adult rights, roles, and responsibilities.

A multifaceted "Biological Beginning"

- Multiple phases of puberty:
 - Adrenarche
 - Growth spurt
 - Gonadarche
- Quick reminder: the brain triggers puberty

SIGNS OF PUBERTY






Rosen (2004)

Puberty is a unique measure of maturation

- Different (and in some ways, maybe better) than age during pre/early adolescence
- Pubertal STAGE vs TIMING vs TEMPO
 - <u>STAGE</u>: how 'mature' are you?
 - <u>TIMING</u>: are you early, on-time, or late? (this is relative to same-age, same-sex peers)
 - <u>TEMPO</u>: how fast (or not) are you moving through puberty?
- Note: after secondary sex characteristics finish maturing in mid-adolescence, hormone levels continue to increase until mid-twenties



Proposed Mechanisms for Puberty's Impact on Adolescent Mental Health


Psychosocial

- Risks of off-time development (maturational deviance)
- Risks of early maturation (developmental readiness, risky social contexts)
- Faster progression through puberty (maturational compression)

Rudolph (2014)

Biological

- Hormones
- Brain development
 - Emphasis on reward, positive valence systems
 - Neglect of social processes




How does puberty impact brain development?: Perspectives from animal models

- Organization-Activation hypothesis about effects of steroid hormones (Sisk & Foster, 2004; Schulz et al., 2009):
 - <u>Organizational effects</u>: Hormones permanently change neural structure (during sensitive periods)
 - <u>Activational effects</u>: Hormones temporarily change activity of neural systems
 - See also Juraska & Willing, 2017

How can we study puberty's impact on *human* brain development & mental health?

- Secondary sexual characteristics
 - Physician/nurse practitioner exams ("Tanner Stages")
 - Self-report (text, line drawings, or photographs)
- Hormones
 - Testosterone, DHEA(-S), Estradiol, Progesterone, FSH, LH
 - How many samples? Saliva? What time of day? Hair?



Specification Curve Analysis of Pubertal Timing & Internalizing

- SCA examines and reports all non-redundant, reasonable, and justifiable measurement/analytic specifications (Simonsohn et al., 2020)
- Reveals the consequences of alternative specifications
- Inferential statistics can be calculated with reference to bootstrapped null distributions





Barendse, Byrne, et al. (under review) <u>https://psyarxiv.com/p5vfb/</u>

Pubertal Timing (12 predictors)

- Age at menarche
- Subjective timing (PDS item)
- Residual-based:
 - PDS
 - Tanner Stage Line Drawings
 - Adrenal, gonadal, composites
 - Hormone levels (T, E2, DHEA)

Controls

- T1 internalizing
- Early life stress before age 7 (CTQ)


Internalizing (7 outcomes)

- Depression sx: (CES-DC)
- Anxiety sx: SCARED-R
- K-SADS: depressive disorder, anxiety disorder
- HiTOP: distress disorder, fear disorder

Other


- Prospective vs. Cross-sectional
- Imputation

Total number of model specifications: 1,288



How to read an SCA:

- Each of the 1,288 model specifications is a vertical line
- Red identifies significant models
- Panel A is the regression coefficient of the predictor – rank ordered by size of that coefficient
- Panel B is the corresponding model specification (includes predictors, outcomes, timepoints, & controls)




Outcome findings:

- Not many significant results when the outcome is depressive symptoms, and the effect size is smaller
- Many more significant results, with larger effect sizes, when the outcome is depressive disorder (DSM-IV) or distress disorder (HiTOP)

	Median point estin [confidence interv		Share of r negative of		Share of sign. results in negative direction		
	observed	р	share	р	share	р	
Depressive	-0.04 [-0.06; -0.03]	<.001	138/184	<.001	5	.580	
symptoms							
Anxiety	-0.04 [-0.06; -0.03]	<.001	135/184	<.001	6	.280	
symptoms							
Internalizing	-0.17 [-0.21; -0.14]	<.001	165/184	<.001	12	.968	
disorder							
Depressive	-0.29 [-0.34; -0.25]	<.001	162/184	<.001	43	<.001	
disorder							
Anxiety	-0.20 [-0.24; -0.17]	<.001	165/184	<.001	13	.950	
disorder							
Distress	-0.20 [-0.29; -0.19]	<.001	154/184	<.001	42	<.001	
disorder							
Fear disorder	-0.12 [-0.15; -0.07]	<.001	150/184	<.001	0	1	

Note: Inferential statistics calculated with reference to bootstrapped null distributions



Predictor findings:

- No significant results when age at menarche or any of the hormones served as predictors
- Residualized (ageadjusted) Line Drawings to estimate Tanner Stage was the most effective predictor: most significant results, largest effect sizes

Median point estimate [CI] Share of rigun, in negative direction Median point estimate in negative direction Share of results in negative direction Share of results in negative direction Median point estimate in negative direction Share of results in negative direction Pesidualized composite 0.012 share p ashare <	6	Prospective					Cross-sectional					Combined							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		Median point e	stimate	Share o	f results	Share	of sign.	Median point e	estimate	Share o	f results	Share	of sign.	Median point e	stimate	Share of res	sults in	Share	of sign.
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		[CI]		in ne	gative	resu	Its in	[CI]		in ne	gative	resu	Its in	[CI]		negative di	rection	results in	n negative
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$				dire	ction									23 20		100		dire	ction
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			_			dire	ction					dire	ction		_				
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$		observed	р	share	р	share	-	observed	р	share	р	share	р	observed	р	share	р	share	р
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Residualized self-	-0.16	<.001	48/66	<.001	6	.232	-0.09	.002	52/66	<.001	0	1	-0.11	<.001	100/112	<.001	6	.914
parent-report PDS stage [-0.23; -0.09] International and	report PDS stage	[-0.21; -0.08]						[-0.14; -0.06]						[-0.15; -0.07]					
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Residualized	-0.15	.002	48/66	<.001	2	.980	-0.12	<.001	50/66	<.001	0	1	-0.13	<.001	98/112	<.001	2	1
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	parent-report PDS	[-0.23; -0.09]						[-0.15; -0.04]						[-0.16; -0.08]					
Tanner stage [-0.36; -0.20] c c [-0.34; -0.19] c c [-0.32; -0.21] col c	stage								·						×				
Residualized puberty composite gonadal composite -0.23 [-0.30; -0.15] <.001 56/66 <.001 17 <.001 -0.19 [-0.26; -0.13] <.001 56/66 <.001 5 .448 -0.22 [-0.26; -0.16] <.001 112/112 <.001 22 <.001 Residualized gonadal composite -0.21 [-0.29; -0.18] <.001	Residualized LD		<.001	56/66	<.001	20	<.001	-0.29	<.001	56/66	<.001	18	<.001	-0.29	<.001	112/112	<.001	38	<.001
puberty composite $[-0.30; -0.15]$ $(-0.25; -0.16]$ $(-0.25; -0.12]$ $(-0.25; -0.12]$ $(-0.25; -0.16]$ $(-0.25; -0.16]$																			
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Residualized		<.001	56/66	<.001	17	<.001	-0.19	<.001	56/66	<.001	5	.448	-0.22	<.001	112/112	<.001	22	<.001
gonadal composite [-0.29; -0.18] [-0.21; -0.10] [-0.23; -0.14]	puberty composite	[-0.30; -0.15]						[-0.26; -0.13]						[-0.26; -0.16]					
composite composite <thcomposite< th=""> <thcomposite< th=""> <thc< td=""><td>Residualized</td><td>-0.21</td><td><.001</td><td>56/66</td><td><.001</td><td>17</td><td><.001</td><td>-0.17</td><td><.001</td><td>53/66</td><td><.001</td><td>7</td><td>.108</td><td>-0.18</td><td><.001</td><td>109/112</td><td><.001</td><td>24</td><td><.001</td></thc<></thcomposite<></thcomposite<>	Residualized	-0.21	<.001	56/66	<.001	17	<.001	-0.17	<.001	53/66	<.001	7	.108	-0.18	<.001	109/112	<.001	24	<.001
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	gonadal	[-0.29; -0.18]						[-0.21; -0.10]						[-0.23; -0.14]					
adrenal composite [-0.23; -0.10] Image: construction of the sector of the sect	composite	•		a															
Self-report 0.01 .384 30/66 .650 2 .994 -0.17 <.001 56/66 <.001 10 .014 -0.11 <.001 82/112 <.001 12 .162 subjective timing -0.17 -0.17 <.001	Residualized	-0.18	<.001	50/66	<.001	9	.014	-0.19	<.001	56/66	<.001	6	.236	-0.18	<.001	106/112	<.001	15	.008
subjective timing [-0.08; 0.03]	adrenal composite	[-0.23; -0.10]										102							
Parent-report subjective timing -0.17 [-0.21; -0.10] <.001 45/66 <.001 2 .982 -0.18 [-0.20; -0.08] <.001 0 1 -0.17 [-0.18; -0.10] <.001 96/112 <.001 2 1 Age at menarche DHEA NA NA NA NA NA NA NA -0.07 [-0.09; 0] .028 38/56 .012 0 1 Residualized DHEA -0.15;06] <.001	Self-report	0.01	.384	30/66	.650	2	.994	-0.17	<.001	56/66	<.001	10	.014	-0.11	<.001	82/112	<.001	12	.162
subjective timing Age at menarche IA NA -0.07 .028 .38/56 .012 0 1 Besidualized -0.15 <.001	subjective timing	[-0.08; 0.03]				1000 C		[-0.22; -0.13]				2010		[-0.15; -0.07]				100000	
Age at menarche NA Image:	Parent-report	-0.17	<.001	45/66	<.001	2	.982	-0.18	<.001	51/66	<.001	0	1	-0.17	<.001	96/112	<.001	2	1
Residualized DHEA -0.05 .001 48/66 .001 0 1 -0.06 .002 44/66 <.001 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.09; 0) 0 1 -0.01 (-0.01; 0) 0 1 -0.01 (-0.01; 0) 0 1 -0.01 (-0.01; 0) 0 1 -0.01 (-0.01; 0) 0 1 -0.03 .170 49/66 <.001 0 1 -0.04 .030 85/112 <.001 0 1 testosterone [-0.08; 0.03] -	subjective timing	[-0.21; -0.10]	5000000000			22262 	15-392195-9	[-0.20; -0.08]	12963, 239743 A		10000000000 1			[-0.18; -0.10]					
Residualized DHEA -0.15 [-0.17;06] <.001 48/66 <.001 0 1 -0.06 [-0.11; 0] .002 44/66 <.001 0 1 -0.11 [-0.12; -0.04] <.001 92/112 <.001 0 1 Residualized testosterone -0.05 [-0.08; 0.03] .060 36/66 .056 0 1 -0.03 [-0.08; 0.01] .170 49/66 <.001	Age at menarche	NA		NA		NA		NA	· · · · · · · · · · · · · · · · · · ·	NA		NA			.028	38/56	.012	0	1
DHEA [-0.17;06]														[-0.09; 0]					
Residualized testosterone -0.05 .060 36/66 .056 0 1 -0.03 .170 49/66 <.001 0 1 -0.04 .030 85/112 <.001 0 1 testosterone [-0.08; 0.03] .002 53/66 <.001	Residualized	-0.15	<.001	48/66	<.001	0	1	-0.06	.002	44/66	<.001	0	1	-0.11	<.001	92/112	<.001	0	1
testosterone [-0.08; 0.03]																			
Residualized estradiol 0.08 .002 53/66 <.001 0 1 -0.03 .396 36/66 .032 0 1 0.03 .084 73/112 .002 0 1	Residualized	-0.05	.060	36/66	.056	0	1	-0.03	.170	49/66	<.001	0	1	-0.04	.030	85/112	<.001	0	1
estradiol [0.04; 0.14] [-0.08; 0.02] [0; 0.07]	testosterone	[-0.08; 0.03]						[-0.08; 0.01]						[-0.07; 0.01]					
	Residualized	0.08	.002	53/66	<.001	0	1	-0.03	.396	36/66	.032	0	1	0.03	.084	73/112	.002	0	1
All prodictors 0.11 c.001 510/61 c.001 75 c.001 0.11 c.001 507/61 c.001 46 20 0.11 c.001 1060/1299 c.001 121 002	estradiol	[0.04; 0.14]												[0; 0.07]					
	All predictors	-0.11	<.001	510/61	<.001	75	<.001	-0.11	<.001	597/61	<.001	46	.29	-0.11	<.001	1069/1288	<.001	121	.002
combined [-0.13;-0.09] 6 [-0.13;-0.10] 6 [-0.13;-0.10]	combined	[-0.13;-0.09]		6				[-0.13;-0.10]		6				[-0.13;-0.10]					

Note: DHEA = Dehydroepiandrosterone; CI = confidence interval; LD = Tanner Stage Line Drawings; PDS = Pubertal Development Scale.

$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	59 (S	Prospective							Cross-sec	ional			Combined						
direction negative direction negative direction regative direction negative direction negative direction negative direction negative direction negative direction negative direction negative direction passerved report PDS stage 0.01 48/66 <001		Median point e	stimate	Share of	of results	Share	of sign.	Median point	estimate	Share of	f results	Share	of sign.	Median point e	stimate	Share of re	sults in	Share	of sign.
Residualized self. -0.16 <.001 48/66 <.001 6 232 -0.09 $[0.02]$ 52/66 <.001 0 1 -0.11 <.001 100/112 <.001 6 .914 Residualized -0.15 $[0.23; -0.08]$.002 48/66 <.001		[CI]				neg	ative	[CI]				neg	ative	[CI]		negative di	rection		
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		observed	р	share	р	share	р	observed	р	share	р	share	р	observed	р	share	р	share	р
Residualized parent-report PDS stage-0.15 [$[-0.3; -0.09]$.002 [$[-0.3; -0.09]$ 48/66 c<.001 22.980 $[-0.15; -0.04]$.001 c50/66 ($[-0.3; -0.09]$.001 c $[-0.15; -0.04]$.001 c $[-0.15; -0.04]$.001 c $[-0.15; -0.04]$.001 c $[-0.32; -0.21]$.001 c $[-0.23; -0.16]$.001 			<.001	48/66	<.001	6	.232		.002	52/66	<.001	0	1		<.001	100/112	<.001	6	.914
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	- V											_							
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$.002	48/66	<.001	2	.980		<.001	50/66	<.001	0	1		<.001	98/112	<.001	2	1
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		[-0.23; -0.09]						[-0.15; -0.04]	а – з					[-0.16; -0.08]	s - 1				
Residualized puberty composite -0.23 (-0.30, -0.15) <.001 56/66 <.001 17 <.001 -0.19 (-0.26, -0.13) <.001 56/66 <.001 56/66 <.001 56/66 <.001 56/66 <.001 56/66 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001 12/112 <.001<	Residualized LD	-0.28	<.001	56/66	<.001	20	<.001	-0.29	<.001	56/66	<.001	18	<.001	-0.29	<.001	112/112	<.001	38	<.001
puberty composite [-0.30; -0.15] [-0.26; -0.13] [-0.26; -0.16] [-0.26; -0.16] [-0.26; -0.16] [-0.26; -0.16] [-0.26; -0.16] [-0.26; -0.16] [-0.26; -0.16] <th< td=""><td>Tanner stage</td><td>[-0.36; -0.20]</td><td></td><td></td><td></td><td></td><td></td><td>[-0.34; -0.19]</td><td></td><td></td><td></td><td></td><td>9 8</td><td>[-0.32; -0.21]</td><td></td><td></td><td></td><td></td><td></td></th<>	Tanner stage	[-0.36; -0.20]						[-0.34; -0.19]					9 8	[-0.32; -0.21]					
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Residualized	-0.23	<.001	56/66	<.001	17	<.001	-0.19	<.001	56/66	<.001	5	.448	-0.22	<.001	112/112	<.001	22	<.001
gonadal composite [-0.29; -0.18] [-0.21; -0.10] [-0.23; -0.14]	puberty composite	[-0.30; -0.15]						[-0.26; -0.13]			3 3			[-0.26; -0.16]	10 10 10 10 10				
composite c	Residualized	-0.21	<.001	56/66	<.001	17	<.001	-0.17	<.001	53/66	<.001	7	.108	-0.18	<.001	109/112	<.001	24	<.001
Residualized adrenal composite -0.18 [-0.23; -0.10] <.001 50/66 <.001 9 .014 -0.19 [-0.22; -0.12] <.001 56/66 <.001 6 .236 -0.18 [-0.21; -0.13] <.001 106/112 <.001 15 .008 Self-report subjective timing ubjective timing for subjective timing subjective timing for subjective timing for subjecti </td <td>gonadal</td> <td>[-0.29; -0.18]</td> <td>100-01000-000</td> <td></td> <td>0.0000000000</td> <td>1000</td> <td>0.00101000</td> <td>[-0.21; -0.10]</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>[-0.23; -0.14]</td> <td>0.0000000000000</td> <td></td> <td></td> <td></td> <td></td>	gonadal	[-0.29; -0.18]	100-01000-000		0.0000000000	1000	0.00101000	[-0.21; -0.10]						[-0.23; -0.14]	0.0000000000000				
adrenal composite [-0.23; -0.10] [-0.22; -0.12] [-0.21; -0.13]	composite																		
Self-report subjective timing 0.01 .384 30/66 .650 2 .994 -0.17 <.001 56/66 <.001 10 .014 -0.11 <.001 82/112 <.001 12 .162 subjective timing [-0.08; 0.03] -0.17 <.001	Residualized	-0.18	<.001	50/66	<.001	9	.014	-0.19	<.001	56/66	<.001	6	.236	-0.18	<.001	106/112	<.001	15	.008
subjective timing parent-report subjective timing subjective timing f-0.21; -0.10] -0.07 <.001 45/66 <.001 2 .982 -0.18 [-0.22; -0.13] <.001 51/66 <.001 0 1 -0.17 [-0.18; -0.10] <.001 96/112 <.001 2 1 Age at menarch NA NA NA NA NA NA NA NA .001 1 -0.07 [-0.09; 0] .028 38/56 .012 0 1 Residualized DHEA -0.15 <.001	adrenal composite	[-0.23; -0.10]	100000000		10000000000	125.		[-0.22; -0.12]						[-0.21; -0.13]	0.0000000000000000000000000000000000000				
Parent-report subjective timing -0.17 <.001 45/66 <.001 2 .982 -0.18 <.001 51/66 <.001 0 1 -0.17 <.001 96/112 <.001 2 1 Age at menarche breadualized DHEA NA NA NA NA NA NA -0.07 .028 38/56 .012 0 1 Residualized DHEA -0.15 <.001	Self-report	0.01	.384	30/66	.650	2	.994	-0.17	<.001	56/66	<.001	10	.014	-0.11	<.001	82/112	<.001	12	.162
subjective timing Age at menarche NA Image: Constraint of the constraint of t	subjective timing	[-0.08; 0.03]	100000000		15123125123	- 25242°		[-0.22; -0.13]				35.02		[-0.15; -0.07]	101000				303337576
Age at menarche NA NA NA NA NA NA NA NA NA -0.07 .028 38/56 .012 0 1 Residualized DHEA -0.15 <.001	Parent-report	-0.17	<.001	45/66	<.001	2	.982	-0.18	<.001	51/66	<.001	0	1	-0.17	<.001	96/112	<.001	2	1
Residualized DHEA -0.15 [-0.17;06] -0.01 48/66 -0.01 0 1 -0.06 [-0.11; 0] .002 44/66 <.001 0 1 -0.01 -0.01 -0.01 92/112 <.001 0 1 Residualized DHEA -0.05 .060 36/66 .056 0 1 -0.03 .170 49/66 <.001	subjective timing	[-0.21; -0.10]	00000000000		2010/02/02/02	- 1958-19 2010-1972 - 19	101111111111	[-0.20; -0.08]	2293232915		10000000	100	1052755	[-0.18; -0.10]	100110021428				
Residualized DHEA -0.15 [-0.17;06] <.001 48/66 <.001 0 1 -0.06 [-0.11; 0] .002 44/66 <.001 0 1 -0.11 [-0.12; -0.04] <.001 92/112 <.001 0 1 Residualized testosterone -0.05 [-0.08; 0.03] .060 36/66 .056 0 1 -0.03 [-0.08; 0.01] .170 49/66 <.001	Age at menarche	NA		NA		NA		NA		NA		NA		-0.07	.028	38/56	.012	0	1
DHEA [-0.17;06] [-0.11; 0] [-0.12; -0.04] <th< td=""><td>1</td><td></td><td></td><td></td><td>1.0000000</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>[-0.09; 0]</td><td></td><td></td><td></td><td></td><td></td></th<>	1				1.0000000									[-0.09; 0]					
Residualized testosterone -0.05 .060 36/66 .056 0 1 -0.03 .170 49/66 <.001 0 1 -0.04 .030 85/112 <.001 0 1 testosterone [-0.08; 0.03] .002 53/66 <.001	Residualized	-0.15	<.001	48/66	<.001	0	1	-0.06	.002	44/66	<.001	0	1	-0.11	<.001	92/112	<.001	0	1
testosterone [-0.08; 0.03] [-0.08; 0.01] [-0.08; 0.01] [-0.07; 0.01]	DHEA	[-0.17;06]						[-0.11; 0]						[-0.12; -0.04]					
Residualized estradiol 0.08 .002 53/66 <.001 0 1 -0.03 .396 36/66 .032 0 1 0.03 .084 73/112 .002 0 1 estradiol [0.04; 0.14] -0.01 510/61 <.001	Residualized	-0.05	.060	36/66	.056	0	1	-0.03	.170	49/66	<.001	0	1	-0.04	.030	85/112	<.001	0	1
estradiol [0.04; 0.14]	testosterone	[-0.08; 0.03]						[-0.08; 0.01]						[-0.07; 0.01]					
All predictors -0.11 <.001 510/61 <.001 75 <.001 -0.11 <.001 597/61 <.001 46 .29 -0.11 <.001 1069/1288 <.001 121 .002	Residualized	0.08	.002	53/66	<.001	0	1	-0.03	.396	36/66	.032	0	1	0.03	.084	73/112	.002	0	1
	estradiol	[0.04; 0.14]						[-0.08; 0.02]						[0; 0.07]					
combined [-0.13;-0.09] 6 [-0.13;-0.10] 6 [-0.13;-0.10]	All predictors	-0.11	<.001	510/61	<.001	75	<.001	-0.11	<.001	597/61	<.001	46	.29	-0.11	<.001	1069/1288	<.001	121	.002
	combined	[-0.13;-0.09]		6				[-0.13;-0.10]		6				[-0.13;-0.10]					

Note: DHEA = Dehydroepiandrosterone; CI = confidence interval; LD = Tanner Stage Line Drawings; PDS = Pubertal Development Scale.

Insights from the SCA

- Strongest associations between pubertal timing & internalizing if:
 - Pubertal timing was measured by **Tanner Stage Line Drawings**
 - Internalizing outcome was case-level disorders (DSM-IV depression or HiTOP distress, coded from K-SADS diagnostic interviews)
- Timing from **hormone** levels was **not** associated with internalizing
 - Suggests **psychosocial** mechansisms may be more meaningful determinants than biological ones in early adolescent girls
- **Prospective** associations more often significant than cross-sectional
 - Suggests initial steps in pubertal process may be particularly salient
 - Controlling for W1 internalizing did not weaken results, indicates likely direction of effect is from pubertal timing \rightarrow internalizing

How does ABCD do it?

- Parent and self report on the Pubertal Development Scale (Petersen et al., 1988)
- 1 saliva sample (DHEA, T; and E2 in girls)

frontiers in Endocrinology

Pediat

UT ARTICLES RESEARCH TOPICS FOR AUTHORS - EDITORIAL BOARD

< Articles

CTION

n,

PERSPECTIVE article

Front. Endocrinol., 05 May 2021 | https://doi.org/10.3389/fendo.2021.608575



A Researcher's Guide to the Measurement and Modeling of Puberty in the ABCD Study[®] at Baseline

Theresa W. Cheng^{1*}, A Lucía Magis-Weinberg², Victoria Guazzelli Williamson¹, Cecile D. Ladouceur³, Sarah L. Whittle⁴, M Megan M. Herting⁵, Kristina A. Uban⁶, Michelle L. Byrne^{1.7}, Marjolein E. A. Barendse¹, Elizabeth A. Shirtcliff⁸ and M Jennifer H. Pfeifer¹





SECTION ABOUT ARTICLES RESEARCH TOPICS FOR AUTHORS 🔻 EDITORIAL BOARD

< Articles

ORIGINAL RESEARCH article


Front. Endocrinol., 18 February 2021 | https://doi.org/10.3389/fendo.2020.549928



Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent **Brain Cognitive Development Study**



🚯 Megan M. Herting^{1,2*†}, 🥦 Kristina A. Uban^{3,4*†}, 🚊 Marybel Robledo Gonzalez^{5,6}, 🚊



2 3 Adrenal PDS


4

Count Count


1000

0-


1



в





Male





С

Female









Handy reviews to bookmark on puberty & neurodevelopment

- Vijayakumar, Op de Macks, Shirtcliff, & Pfeifer (2018) – all neuroimaging modalities
- Byrne et al. (2017) adrenarche
- Herting & Sowell (2017) structure
- Goddings et al. (2019) structure
- Dai & Sherf (2019) fMRI/EEG
- Barendse & Pfeifer (forthcoming Handbook of Dev Cog Neuro)

Puberty and global cortical GM (Vijayakumar et al., 2018)


	Without Age		With	Age	Age	Sample size
	Female	Male	Female	Male		
Pubertal stage						
Peper et al., 2009b					9	214
Koolschijn et al., 2014					8-25	215
Bramen et al., 2011					10-14	80
Pfefferbaum et al., 2015					12-22	674
Testosterone				8		
Peper et al., 2009c					10-15	78
Koolschijn et al., 2014					8-25	215
Bramen et al., 2011					10-14	80
Paus et al., 2010					12-18	419
Estradiol						
Peper et al., 2009c					10-15	78
Koolschijn et al., 2014					8-25	215








Puberty and regional cortical GM (cross-sectional)



 Consistent decreases in frontal, temporal GM with self-report and hormonal indices of puberty (timing)

Puberty and subcortical GM



Puberty and WM volume/density, FA, & MD

A)	Volu	me/density	В)		FA	м	D
	Without	With age		Female	Male	Female	Male
Dubertal stage	age	U	Pubertal stage				
Pubertal stage	CC		Bava et al., 2012		CST, SCR	ILF, force	ps major
Chavarria et al., 2014	and the second		Herting et al., 2012		insula		
Pfefferbaum et al., 2015	global			superior	superior front		
Perrin et al., 2009	all lobes			front			
Peper et al., 2009b		occipital	Menzies et al., 2015		SLF, ILF, CLT, CST		SLF, ILF, CLT, CST
Pangelinan et al., 2016		CST	Testosterone				
Testosterone			Barendse et al., 2018				
Paus et al., 2010	global				superior temp,		
Herve et al., 2009	CST	CST	Herting et al., 2012	precentral	front, angular gyrus, thalamus,		superior front
Perrin et al., 2008	global				CC, IC		nom
Peper et al., 2009c		global/regional	Peper et al., 2015			subcortico-	
Pangelinan et al., 2016		CST				temp	SLF, ILF,
Estradiol			Menzies et al., 2015 *				CLT, CST
Paus et al., 2010		global/regional	Estradiol				
			Herting et al., 2012	angular gyrus, IC, SLF	Cingulum, superior front, precuneus, thalamus		
			Peper et al., 2015				
			Menzies et al., 2015 *				SLF, ILF, CLT, CST

Summary of Vijayakumar et al. (2018)


- PFC is among the most consistently associated regions with pubertal maturation (superior/inferior frontal and anterior cingulate cortices)
- Amgydala and hippocampus structure are associated with pubertal stage (varies by sex); ventral striatum activation to reward receipt associated with pubertal stage and testosterone
- Functional activation patterns are still somewhat unclear (see also Dai & Scherf, 2019)
- Longitudinal pubertal and hormonal processes, rather than absolute stages/levels, more likely to be informative

Emerging evidence brain development mediates puberty \rightarrow mental health link

https://medicine.unimelb.edu.au/research-groups/psychiatry/melbourne-neuropsychiatry-centre/social-affective-neurodevelopment-sand

- Larger pituitary volumes mediated relationships between:
 - Early pubertal timing and increased depressive symptoms (Whittle et al., 2012)
 - Greater DHEA levels and increased social anxiety symptoms (Murray et al., 2016)
- Larger hippocampal volume mediated link between greater T levels and increased depressive symptoms in girls (Ellis et al., 2019)
- Weaker activation in posterior insula elicited by happy emotional expressions mediated link between greater DHEA levels and increased externalizing symptoms (Whittle et al., 2015)
- Amygdala connectivity during emotion processing mediated link between early adrenarcheal timing and increased anxiety symptoms (Barendse et al., 2019)

Heuristic Model impact of puberty on adolescent mental health



II. Early Life Stress



Early Life Stress (ELS) and Mental Health

- Conceptualizations of ELS have moved from cumulative risk to dimensional approaches that include threat, deprivation, and unpredictability (McLaughlin & Sheridan, 2016; Ellis et al., 2009)
- ELS linked to ~45% of all child-onset mental health disorders, and ~30% of all adult-onset ones (McLaughlin et al., 2010)
- Body and brain adaptations to ELS can have negative long-term consequences (Herzberg & Gunnar, 2020)
 - Drives and thereby remodels HPA axis functioning
 - Deviations from healthy levels of basal cortisol can impact behavior & brain structure/function

Accelerated Maturation/Stress Acceleration

- Psychosocial stress accelerates biological maturation, including early pubertal development (Belsky et al., 1991; Del Giudice et al., 2011)
- ELS-advanced pubertal timing associated with developmental of psychopathology (Colich et al., 2019)
- ELS may cause premature maturation of emotion-related brain circuitry (Callaghan & Tottenham, 2016)




ELS and human brain development

- Structure
 - Differences in thickness/volume of amygdala, hippocampus, medial and lateral PFC, and superior parietal cortex
- Function
 - Increased amygdala response to/enhanced processing of negative emotions
 - Blunted VS response and impaired processing of rewards/positive emotions
 - Mixed effects in lateral PFC
- Emerging evidence in relation to mental health:
 - Reward-related responses in VS mediated link between community disadvantage and anxiety (Marshall et al., 2018)
 - VS-mPFC connectivity explained ~ 10% of variance in ELS-internalizing link (Hanson et al., 2018)
 - See also Marusak et al., 2015, 2017; Fareri et al., 2017



Possible developmental trade-off (and implications for timing of assessments)



How does ABCD do it?



Neurobiology of Stress Volume 10, February 2019, 100157



Stress exposures, neurodevelopment and health measures in the ABCD study

Elizabeth A. Hoffman ^a $^{\circ}$ ¹ $^{\Box}$, Duncan B. Clark ^b, Natalia Orendain ^c, James Hudziak ^d, Lindsay M. Squeglia ^e, Gayathri J. Dowling ^a

Show more $\,\,\smallsetminus\,\,$

+ Add to Mendeley 😪 Share 🔊 Cite

https://doi.org/10.1016/j.ynstr.2019.100157 Under a Creative Commons license Get rights and content open access

Abstract

The Adolescent Brain Cognitive Development (ABCD) Study, a large, <u>longitudinal study</u> of brain development and child health, is uniquely positioned to explore relationships among stress, <u>neurodevelopment</u>, and

Adverse Childhood Experiences (ACEs) Domain ^a	ABCD Baseline Assessment (Parent, Youth)	Description
Abuse:		
Emotional abuse	Not assessed	N/A
Physical abuse	Family Environment Scale (parent and youth); KSADS-5, PTSD module (parent)	Social-environmental characteristics of family function; youth exposure to and experience of trauma
Sexual abuse	KSADS-5, post-traumatic stress disorder module (parent)	Youth exposure to and experience of trauma
Household		
Challenges:		
Mother treated violently	KSADS-5, PTSD module (parent)	Youth exposure to and experience of trauma
Household substance abuse	Family History Assessment; Adult Self-report (parent)	Family history of psychopathology and substance use; criminal behavior
Mental illness in household	Family History Assessment; Adult Self-report (parent)	Family history of psychopathology and substance use; criminal behavior
Parental separation or divorce	Demographics Survey (parent)	Family demographics, including race, gender, family structure, SES, education and occupation
Criminal household member	Family history Assessment (parent)	Family history of psychopathology and substance use; criminal behavior
Neglect:		
Emotional neglect	CRPBI Acceptance Subscale (youth)	Youth perception of caregiver acceptance
Physical neglect	Parental Monitoring (youth); Demographics Survey (parent)	Youth perception of parental supervision; family demographics (economic hardship, e.g., food insecurity)

Conclusions

- A multiverse of ways to measure these mechanisms
- For both puberty and early life stress, method and timing of asessments is key!
 - Essential to match these with your research question
- ABCD may offer opportunities to test path models whereby earlier developmental effects (puberty, ELS, environment, parenting) launch cascading relationships between brain, behavior (social, emotional, motivational, regulatory), and mental health